Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Spruce Biosciences, Inc. - Common Stock (NQ:SPRB)

52.70 +3.60 (+7.34%)
Streaming Delayed Price Updated: 11:01 AM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 33,695
Open 49.18
Bid (Size) 52.00 (100)
Ask (Size) 53.41 (100)
Prev. Close 49.10
Today's Range 49.02 - 53.25
52wk Range 7.260 - 240.00
Shares Outstanding 40,710,692
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
From Spruce Biosciences, Inc.
Via Business Wire

Performance

YTD
-41.9%
-41.9%
1 Month
-7.0%
-7.0%
3 Month
-12.0%
-12.0%
6 Month
-40.4%
-40.4%
1 Year
+437.8%
+437.8%

More News

Read More
News headline image
Spruce Biosciences to Participate in Upcoming Conferences in June
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences to Present at Upcoming Investor Conferences in March
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy ↗
Via Stocktwits
News headline image
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Spruce Biosciences Inc (NASDAQ:SPRB) Reports Q3 2025 Results, Secures $50M Financing and Breakthrough Therapy Designation ↗
Via Chartmill
News headline image
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Spruce Biosciences Announces $50.0 Million Private Placement Financing
From Spruce Biosciences, Inc.
Via Business Wire
News headline image
Top stock movements in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga

Frequently Asked Questions

Is Spruce Biosciences, Inc. - Common Stock publicly traded?
Yes, Spruce Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Spruce Biosciences, Inc. - Common Stock trade on?
Spruce Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Spruce Biosciences, Inc. - Common Stock?
The ticker symbol for Spruce Biosciences, Inc. - Common Stock is SPRB on the Nasdaq Stock Market
What is the current price of Spruce Biosciences, Inc. - Common Stock?
The current price of Spruce Biosciences, Inc. - Common Stock is 52.70
When was Spruce Biosciences, Inc. - Common Stock last traded?
The last trade of Spruce Biosciences, Inc. - Common Stock was at 06/12/26 11:01 AM ET
What is the market capitalization of Spruce Biosciences, Inc. - Common Stock?
The market capitalization of Spruce Biosciences, Inc. - Common Stock is 2.15B
How many shares of Spruce Biosciences, Inc. - Common Stock are outstanding?
Spruce Biosciences, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.